TRAF2 and coronary artery disorder: Finally, CAD patients with high levels of platelet-ACKR3 showed reduced ex vivo platelet aggregation in response to thrombin-related activating peptide (TRAP) (platelet-ACKR3 high (2nd/3rd tertile) vs. low (1st tertile); mean AUC ± S.E.M.; 69.4 ± 2.0 vs. 82.8 ± 2.6, p < 0.001) (Fig. 1c).